RELAPSED OR REFRACTORY MANTLE CELL LYMPHOMA (MCL)
Clinical trials for RELAPSED OR REFRACTORY MANTLE CELL LYMPHOMA (MCL) explained in plain language.
Never miss a new study
Get alerted when new RELAPSED OR REFRACTORY MANTLE CELL LYMPHOMA (MCL) trials appear
Sign up with your email to follow new studies for RELAPSED OR REFRACTORY MANTLE CELL LYMPHOMA (MCL), keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New hope for tough lymphoma: experimental drug ICP-248 targets relapsed mantle cell cancer
Disease control Recruiting nowThis study tests an experimental drug called ICP-248 in 75 adults whose mantle cell lymphoma has returned or stopped responding to prior therapy. The main goal is to see how many patients' tumors shrink or disappear. Researchers will also monitor side effects and how long any ben…
Matched conditions: RELAPSED OR REFRACTORY MANTLE CELL LYMPHOMA (MCL)
Phase: PHASE2 • Sponsor: Beijing InnoCare Pharma Tech Co., Ltd. • Aim: Disease control
Last updated Jul 25, 2026 00:00 UTC
-
New combo therapy offers hope for Tough-to-Treat lymphoma
Disease control Recruiting nowThis study tests a combination of two drugs, glofitamab and lenalidomide, in people with a fast-growing type of lymphoma (mantle cell lymphoma) that has come back or not responded to treatment, especially after a BTK inhibitor stopped working. About 43 adults will receive the dru…
Matched conditions: RELAPSED OR REFRACTORY MANTLE CELL LYMPHOMA (MCL)
Phase: PHASE2 • Sponsor: Peking University Third Hospital • Aim: Disease control
Last updated Jun 27, 2026 11:00 UTC